跳至主要内容
临床试验/RPCEC00000314
RPCEC00000314招募中未知

Population impact of intervention based on the administration of a single dose of the Outer Membrane Vesicle (OMV) complex contained in VA-MENGOC-BC to stimulate the innate response against SARS-CoV-2 (COVID-19) - VME-CORONA

Finlay Vaccine Institute (IFV)0 个研究点目标入组 115,000 人开始时间: 2020年5月22日最近更新:

试验速览

阶段
未知
状态
招募中
发起方
入组人数
115,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomized controlled trial. Masking: Open. Control group: No intervention. Assignment: Parallel. Purpose: Prevention

入排标准

年龄范围
19 years 至 one(—)
性别
All

入选标准

  • 1. Male or female subject =19 years resident in the areas of intervention of Popular Councils of the Plaza and Centro Habana municipalities, of Havana
  • 2. Subject that gives the Informed Consent

排除标准

  • 1. Subject with a history of acute allergic processes.
  • 2. Subject with a history of acute infectious disease at the time of vaccination or in the 7 days prior to the administration of the vaccine
  • 3. Subject with a history of chronic diseases in the decompensation phase
  • 4. Pregnant women-Subjects with known hypersensitivity to any component of the vaccine
  • 5. Subjects with immunomodulatory treatment (immunostimulant or immunosuppressant)

研究者

发起方
Finlay Vaccine Institute (IFV)

相似试验

VA-MENGOC-BC to stimulate the innate response... | 临床试验